Effect of zoledronic acid in patients with renal cell cancer and bone metastasis.
Phase of Trial: Phase IV
Latest Information Update: 17 Apr 2013
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Bone metastases; Renal cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 16 Oct 2012 New source identified and integrated (German Clinical Trials Register DRKS00004119).
- 26 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Nov 2005 New trial record.